AccueilAccueil>Research>Teams>Ronan ROUSSEL

Diabetes vascular complications

Despite recent therapeutic advances, especially with the use of renin-angiotensin system blockers, the prevention of cardiovascular and renal complications of diabetes and obesity remains partial. Our team aims to study cellular and molecular mechanisms causally related to the development of type 1 and type 2 diabetes, obesity, and their complications. The objective is to identify new risk factors and provide novel targets for primary and secondary prevention. Our project focuses on the role of two biologically potent and functionally related vasomotor peptide systems, the kallikrein-kinins system, and vasopressin.

Using genetic mouse models, pharmacological tools, and clinical investigation, our recent works documented a) a protective role of kallikrein and kinins against development of heart and kidney damage in ischemic or metabolic diseases, b) a role of water intake and vasopressin secretion in the pathogenesis of both glucose intolerance and renal dysfunction in established diabetes. The animal studies are combined with clinical investigation, epidemiological and genetic human studies in established cohorts. So, we are able to test the clinical relevance of experimental findings

We are also involved in evaluation of drugs used against diabetes and its complications to discover unexpected beneficial or detrimental effects. In this regard, we design and conduct proof-of-concept clinical trials, and have a large program of data mining of large registries and epidemiological data extracted from clinical trials. This program is developed both on an academic basis and in collaboration with pharmaceutical companies.

 Team Leader : Ronan ROUSSEL (Pr)

Team Members :

François ALHENC-GELAS (Dr), Konstantinos ARAPIS (Dr), Lise BANKIR (Dr), Nadine BOUBY (Dr), Frédéric FUMERON (Pr), Boris HANSEL (Dr), Joel MENARD (Pr), Michel MARRE (Pr),  Louis POTIER (Dr), Florence TRAVERT (Dr), Gilberto VELHO (Dr).

Bertrand BAUCHAT (Tech), Catherine CHOLLET (Tech), Maryse GENDRY (Tech).

Ray EL BOUSTANI (PhD), Abdul Kayoum MOUTAIROU (PhD), Manuel SANCHEZ (PhD). 

Administration : Florence BORDU

Contact details: 33 1 44 27 63 93 / Fax : 33 1 44 27 64 21


Selected Publications

    • Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus MF, Magnan C, Philippe E, Paradis V, Foufelle F, Hainault I, Enhorning S, Velho G, Roussel R, Bankir L, Melander O, Bouby N (2015) Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia, (DOI) 10.1007/s00125-015-3496-9
    • Desposito D, Potier L, Chollet C, Gobeil F, Jr., Roussel R, Alhenc-Gelas F, Bouby N, Waeckel L (2015) Kinin receptor agonism restores hindlimb postischemic neovascularization capacity in diabetic mice. J Pharmacol Exp Ther 352 (2): 218-226
    • Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, Lantieri O, Balkau B, Bouby N, Bankir L, Bichet DG (2014) Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab 99 (12): 4656-4663
    • Potier L, Waeckel L, Fumeron F, Bodin S, Fysekidis M, Chollet C, Bellili N, Bonnet F, Gusto G, Velho G, Marre M, Alhenc-Gelas F, Roussel R, Bouby N, Group DS (2014) Tissue kallikrein deficiency, insulin resistance, and diabetes in mouse and man. J Endocrinol 221 (2): 297-308
    • Mohammedi K, Bellili-Munoz N, Driss F, Roussel R, Seta N, Fumeron F, Hadjadj S, Marre M, Velho G (2014) Manganese superoxide dismutase (SOD2) polymorphisms, plasma advanced oxidation protein products (AOPP) concentration and risk of kidney complications in subjects with type 1 diabetes. PLoS One 9 (5): e96916
    • Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F, Potier L, Bellili-Munoz N, Taveau C, Alhenc-Gelas F, Bankir L, Marre M, Roussel R (2013) Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 36 (11): 3639-3645
    • Potier L, Waeckel L, Vincent MP, Chollet C, Gobeil F, Jr., Marre M, Bruneval P, Richer C, Roussel R, Alhenc-Gelas F, Bouby N (2013) Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes. J Pharmacol Exp Ther 346 (1): 23-30
    • Bankir L, Bouby N, Ritz E (2013) Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 9 (4): 223-239

Picture Site: Vasculo-tubulars relations in mammals kidney

View all publications

Link to PubMed


Les Outils